Skip to main content
. 2007 Aug 27;153(3):410–419. doi: 10.1038/sj.bjp.0707434

Table 1.

Pharmacology of PGF2α-amides

PGF C1-substituent Feline iris
Swiss 3T3 cell
Rabbit jugular vein
Guinea-pig ileum
Guinea-pig vas deference
Human platelets (aggregation)
Human platelets
  •Prostamide •FP •FP •EP4 •DP1 •EP1 •EP3 •TP •DP1, •IP
Inline graphic 21 18 000 643 NA 794 >10 000
Inline graphic 28 13 300
Inline graphic 35 250 >10 000 >10 000
Inline graphic 19 281 NA >10 000
Inline graphic 60 17 800 NA >10 000 NA
Inline graphic 158 17 800 NA >10 000 NA
Inline graphic 258 20 734
Inline graphic 771 3649
Inline graphic 57 4285 1277 >10 000 1590 NA NA
Inline graphic 158 2860
Inline graphic 4500 >10 000 3649

Abbreviations: NA, not active; prostamide, prostaglandin-ethanolamide.

Values are EC50 (nM). Experiments involved at least four replicates. Receptor subtype involvement is given (•) under the description of each preparation. Physiological responses are as follows: feline iris=contraction; Swiss 3T3 cells=Ca2+ ↑; rabbit jugular vein=relaxation; guinea-pig ileum=contraction; guinea pig vas deferens=inhibition of field stimulated contraction; human platelets (TP)=aggregation; human platelets (DP, IP)=inhibition of ADP induced aggregation.